Tokai Pharmaceuticals Reports $10M Round, Developing Drug for Prostate Cancer
Xconomy --Tokai Pharmaceuticals, a Cambridge, MA-based drug developer, has landed $10 million of a proposed $22 million round of private equity financing, according to an SEC filing. The startup says that its main focus is advancing a new drug for prostate cancer that is unable to be treated with standard testosterone-blocking therapies, according to its website.